Clinical Trial Update: Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial sponsored by Emory University is investigating repurposed atovaquone for platinum-resistant ovarian cancer, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian High Grade Serous Adenocarcinoma
• Platinum-resistant Ovarian Carcinoma

Drugs mentioned

• Atovaquone (Atovaquone)

Snippet

Sponsor: Emory University | Conditions: Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Status: RECRUITING